Scaling Up for First Product Launch: Seven Hazards to Avoid Pierre Jacquet, M.D., Ph.D. Peter Rosenorn Aditya Natarajan Read more
Related Practice Life Sciences & Pharma As the margin for error in the drug launch cycle continues to erode, emerging biopharma companies face a growing urgency to double down on scaling up for that first launch. 01022024150106
Article Mental and Behavioral Health Exploring the Psychedelics Landscape: Looking Ahead to Funding in 2024 February 20, 2024
Executive Insights Business Services Benefits of the 4-Day Week: The Jury Is Still Out October 31, 2023
Article Digital AI Has Moved Beyond Hype — It Is Driving Performance and Deployment Is Widespread September 20, 2023
Video / Webinar Life Sciences & Pharma Meet L.E.K.'s Pharmaceutical Services Practice September 20, 2023